Arcus Biosciences (RCUS) Revenue Growth (3y) (2020 - 2026)
Arcus Biosciences (RCUS) Revenue Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.39 Bn | 467.60 Bn | 1.35 Bn | 50.07% |
| 5 | Vertex Pharmaceuticals | 122.08 Bn | 114.83 Bn | 2.59 Bn | 7.94% |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | 4.47% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | 79.44% |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 54.05% |
| 10 | Arcus Biosciences | 3.53 Bn | 2.71 Bn | - | -12.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.06% |
| Dec 31, 2025 | -0.99% |
| Sep 30, 2025 | -7.64% |
| Jun 30, 2025 | 80.96% |
| Mar 31, 2025 | 15.87% |
| Dec 31, 2024 | -58.15% |
| Sep 30, 2024 | 71.83% |
| Jun 30, 2024 | 60.34% |
| Mar 31, 2024 | 148.40% |
| Dec 31, 2023 | 13.85% |
| Sep 30, 2023 | -20.85% |
| Jun 30, 2023 | 154.95% |
| Mar 31, 2023 | 142.64% |
| Dec 31, 2022 | 51.64% |
| Sep 30, 2022 | 166.17% |
| Jun 30, 2022 | 148.95% |
| Mar 31, 2022 | 117.48% |
| Dec 31, 2021 | 510.04% |
| Sep 30, 2021 | 30.15% |
| Jun 30, 2021 | 96.34% |